Contenuto

Elenco pubblicazioni della Struttura Semplice dipartimentale Oncologia Medica dei Tumori Mesenchimali dell'Adulto

  1. Casali P.G., Sanfilippo G.R.: Uterine sarcomas: a multidisciplinary challenge. Eur J Cancer 2011; 47: Suppl. 3: 326-327
  2. Casali P.G.: Medical oncology: the long-awaited prize of recognition. (Editorial) Ann Oncol 2011; 22: 1695-1697
  3. Da Riva L., Bozzi F., Mondellini P., Miccichè F., Fumagalli E., Vaghi E., Tarantino E., Huber V., Gronchi A., Tamborini E., Pierotti M.A., Pilotti S., Bongarzone I.: Proteomic detection of a large amount of SCGF? in the stroma of GISTs after imatinib therapy. J Transl Med 2011; 9: 158
  4. Dileo P., Pricl S., Tamborini E., Negri T., Stacchiotti S., Gronchi A., Posocco P., Laurini E., Coco P., Fumagalli E., Casali P.G., Pilotti S.: Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. Int J Cancer 2011; 128: 983-990
  5. Gatta G., van der Zwan J.M., Casali P.G., Siesling S., Dei Tos A.P., Kunkler I., Otter R., Licitra L., Mallone S., Tavilla A., Trama A., Capocaccia R., The RARECARE working group: Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-2511 [IF 4,944]
  6. Grignani G., Palmerini E., Stacchiotti S., Boglione A., Ferraresi V., Frustaci S., Comandone A., Casali P.G., Ferrari S., Aglietta M.: A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-? or -?: An Italian Sarcoma Group study. Cancer 2011; 117: 826-831
  7. Gronchi A., Miceli R., Colombo C., Collini P., Stacchiotti S., Olmi P., Mariani L., Bertulli R., Fiore M., Casali P.G.: Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann Oncol 2011; 22: 1675-1681
  8. Italiano A., Laurand A., Laroche A., Casali P.G., Sanfilippo G.R., Le Cesne A., Judson I., Blay J.Y., Ray-Coquard I., Nieto A., Tercere J.C., Jemeno J., Robert J., Pourquier P.: ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011; 117: 3445-3456
  9. Joensuu H., De Braud F., Grignani G., De Pas T., Spitalieri G., Coco P., Spreafico C., Boselli S., Toffalori F., Bono P., Jalava T., Kappeler C., Aglietta M., Laurent D., Casali P.G.: Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011; 104: 1686-1690
  10. Ardoino I., Miceli R., Berselli M, Mariani L., Biganzoli E., Fiore M., Collini P., Stacchiotti S., Casali P.G., Gronchi A.: Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer 2010; 116: 2429-2436
  11. Barisella M., Collini P., Orsenigo M., Aiello A., Paties C.T., Dileo P., Pilotti S.:Unusual myogenic and melanocytic differentiation of soft tissue pPNETs: an immunohistochemical and molecular study of 3 cases. Am J Surg Pathol 2010; 34: 1002-1006
  12. Bonvalot S., Miceli R., Berselli M., Causeret S., Colombo C., Mariani L., Bouzaiene H., Le Pèchoux C., Casali P.G., Le Cesne A., Fiore M., Gronchi A.: Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 2010; 17: 1507-1514
  13. Casali P.G., Blay J.Y., Dileo P., Ferrari A., Gronchi A.: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl.5): 98-102
  14. Casali P.G., Blay J.Y., Dileo P., Gronchi A., Ferrari A.: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): 198-203
  15. Casali P.G., Sanfilippo G.R., D'Incalci M.: Trabectedin therapy for sarcomas. Curr Opin Oncol 2010; 22: 342-346
  16. Casali P.G.: Do rare cancers deserve specific strategies for cancer research? (Reflection and Reaction) Lancet Oncol 2010; 11: 506-507
  17. Frapolli R., Tamborini E., Virdis E., Bello E., Tarantino E., Marchini S., Grosso F., Sanfilippo G.R., Gronchi A., Tercero J.C., Peloso G., Casali P.G., Pilotti S., D'Incalci M.: Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. Clin Cancer Res 2010; 16: 4958-4967
  18. Gatta G., Capocaccia R., Trama A., Martinez-Garcia C., Berrino F., Casali P.G., Gronchi A., Licitra L., Olmi P., Ruzza M., Sowe S., Tagliabue G., Contiero P., the RARECARE Working Group: The Burden of Rare Cancers in Europe. Adv Exp Med Biol 2010; 686: 285-303
  19. Germano G., Frapolli R., Simone M., Tavecchio M., Erba E., Pesce S., Pasqualini F., Grosso F., Sanfilippo G.R., Casali P.G., Gronchi A., Virdis E., Tarantino E., Pilotti S., Greco A., Nebuloni M., Galmarini C.M., Tercero J.C., Mantovani A., D'Incalci M., Allavena P.: Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235-2244
  20. Gronchi A., Lo Vullo S., Colombo C., Collini P., Stacchiotti S., Mariani L., Fiore M., Casali P.G.: Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010; 251: 506-511
  21. Hogendoorn P.C.W., on behalf of the ESMO/EUROBONET Working Group, Athanasou N., Bielack S., De Alava E., Dei Tos A.P., Ferrari S., Gelderblom H., Grimer R., Hall K.S., Hassan B., Hogendoorn P.C.W., Jurgens H, Paulussen M., Rozeman L., Taminiau A.H.M., Whelan J., VanelD., Casali P.G., Dileo P., Ferrari A., Gronchi A.: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 5): 204-213
  22. Mussi C., Ronollenfitsch U., Jakob J., Tamborini E., Reichardt P., Casali P.G., Fiore M., Hohenberger P., Gronchi A.: Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21: 403-408
  23. Negri T., Virdis E., Brich S., Bozzi F., Tamborini E., Tarantino E., Jocollè J., Cassinelli G., Grosso F., Sanfilippo G.R., Casalini P., Greco A., Pierotti M.A., Pilotti S.: Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res 2010; 16: 3581-3593
  24. Pennacchioli E., Fiore M., Collini P., Radaelli S., Dileo P., Stacchiotti S., Casali P.G., Gronchi A.: Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol 2010; 17: 3229-3233
  25. Perrone A., Jocollè J., Pennati A., Deraco M., Baratti D., Brich S., Orsenigo M., Tarantino E., De Marco C., Bertan C., Cabras A., Bertulli R., Pierotti M.A., Zaffaroni N., Pilotti S.: Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 2010; 46: 2837-2848
  26. Rossi S., Gasparotti D., Toffolatti L., Pastrello C., Gallina G., Marzotto A., Sartor C.
  27. Barbareschi M., Cantaloni C., Messerini L., Bearzi I., Arrigoni G., Mazzoleni G., Fletcher J.A., Casali P.G., Talamini R., Maestra R., Dei Tos A.P.: Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010; 34: 1480-1491
  28. Stacchiotti S., Casali P.G., Lo Vullo S., Mariani L., Palassini E., Mercuri M., Alberghini M., Pilotti S., Zanella L., Gronchi A., Picci P.: Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2010; 17: 211-219
  29. Stacchiotti S., Grosso F., Negri T., Palassini E., Morosi C., Pilotti S., Gronchi A., Casali P.G.: Tumor response to sunitinib malate observed in clear-cell sarcoma. Letter Ann Oncol 2010; 21: 1130-1131
  30. Stacchiotti S., Negri T., Palassini E., Conca E., Gronchi A., Morosi C., Messina A., astorino U., Pierotti M.A., Casali P.G., Pilotti S.: Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010; 9: 286-1297
  31. Tamborini E., Virdis E., Negri T., Orsenigo M., Brich S., Conca E., Gronchi A., Stacchiotti S., Manenti G., Casali P.G., Pierotti M.A., Pilotti S.: Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro-Oncology 2010; 12: 776-789
  32. Vincenzi B., Perrone G., Santini D., Grosso F., Silletta M., Frezza A., Rossi S., Russo A., Rabitti C., Gebbia N., Badalamenti G., Casali P.G., Onetti Muda A., Dei Tos A.P., Tonini G.: PML down-regulation in soft tissue sarcomas. J Cell Physiol 2010; 224: 644-648
  33. Baratti D., Kusamura S., Cabras A., Dileo P., Laterza B., Deraco M.: Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2009; 16: 463-
  34. Bielack S., Carrle D., Casali P.G., On behalf of the ESMO Guidelines Working Group: Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl.4) iv: 37-39
  35. Casali P.G., Jost L., Reichardt P., Schlemmer M., Blay J.Y., On behalf of the ESMO Guidelines Working Group: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl.4) iv: 64-67
  36. Casali P.G., Jost L., Sleijfer S., Verweij J., Blay J.Y., On behalf of the ESMO GuidelinesWorking Group: Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl.4) iv: 32-36
  37. Conca E., Negri T., Gronchi A., Fumagalli E., Tamborini E., Pavan G.M., Fermeglia M., Pierotti M.A., Pricl S., Pilotti S.: Activate and resist: L576P-KIT in GIST. Mol Cancer Ther 2009; 8: 2491-2495
  38. Demetri G.D., Casali P.G., Blay J.Y., von Mehren M., Morgan J.A., Bertulli R., Ray-
  39. Coquard I., Cassier P., Davey M., Borghaei H., Pink D., Debiec-Rychter M., Cheung W., Bailey S.M., Veronese M.L., Reichardt A., Fumagalli E., Reichardt P.: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib- resistant gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 5910-5916
  40. Fiore M., Palassini E., Fumagalli E., Pilotti S., Tamborini E., Stacchiotti S., Pennacchioli E., Casali P.G., Gronchi A.: Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009; 35: 739-745
  41. Fiore M., Rimareix F., Mariani L., Domont J., Collini P., Le Pechoux C., Casali P.G., Le Cesne A., Gronchi A., Bonvalot S.: Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593
  42. Forni C., Minuzzo M., Virdis E., Tamborini E., Simone M., Tavecchio M., Erba E., Grosso F., Gronchi A., Aman P., Casali P.G., D'Incalci M., Pilotti S., Mantovani R.: Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009; 8: 449-457
  43. George S., Blay J.Y., Casali P.G., Le Cesne A., Stephenson P., DePrimo S.E., Harmon C.S., Law C.N.J., Morgan J.A., Ray-Coquard I., Tassell V., Cohen D.P., Demetri G.D.: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45: 1959-1968
  44. Gronchi A., Bonvalot S., Le Cesne A., Casali P.G.: Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma. (Letter) J Clin Oncol 2009; 27: 2106-2107 [
  45. Gronchi A., Judson I., Nishida T., Poveda A., Martin J., Reichardt P., Casali P.G., Le Cesne A., Hohenberger P., Blay J.Y.: Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 2009; 45: 1103-1106
  46. Gronchi A., Lo Vullo S., Fiore M., Mussi C., Stacchiotti S., Collini P., Lozza L., ennacchioli E., Mariani L., Casali P.G.: Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009; 27: 24-30
  47. Grosso F., Sanfilippo G.R., Virdis E., Piovesan C., Collini P., Dileo P., Morosi C., Tercero J.C., Jimeno J., D'Incalci M., Gronchi A., Pilotti S., Casali P.G.: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009; 20: 1439-1444
  48. Le Cesne A., Van Glabbeke M., Verweij J., Casali P.G., Findlay M., Reichart P., Issels R., Judson I., Schoffski P., Leyvraz S., Bui B., Hogendoorn P.C.W., Sciot H., Blay J.Y.: Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27: 3969-3974
  49. Mertens F., Antonescu C.R., Hohenberger P., Ladanyi M., Modena P., D'Incalci M.,
  50. Casali P.G., Aglietta M., Alvegard T.: Translocation-related sarcomas. Semin Oncol
  51. 2009; 36: 312-323 [IF 3,956] [IF norm 3]
  52. Micheli A., Sanz N., Mwangi-Powell F., Coleman M.P., Neal C., Ullrich A., Travado L., Santini L.A., Grazzi L., De Lorenzo F., Costa A., Dangou J.M., Bisanti L., Seniori Costantini A., Abu-Rmeileh N., Kamal M., Federico M., Saracci R., Rennert G., Stefanini A., Cavalli F., Cazap E., Redmond G., O'Reilly S., Muti P., Casali P.G., Gatta G., Ferrari A., Koifman S., Bah E., Pastore G., Barr R., Lombardo C., Frazzingaro C., Ciampichini R., Baili P., and the ICCC-3 Session B group: International collaborations in cancer control and the Third International Cancer Control Congress. Tumori 2009; 95: 579-596
  53. Negri T., Bozzi F., Conca E., Brich S., Gronchi A., Bertulli R., Fumagalli E., Pierotti
  54. M.A., Tamborini E., Pilotti S.: Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol 2009; 217: 103-112
  55. Paulussen M., Bielack S., Jurgens H., Casali P.G., On behalf of the ESMO Guidelines Working Group: Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl.4)iv: 40-42
  56. Pilla L., Rivoltini L., Patuzzo R., Marrari A., Valdagni R., Parmiani G.: Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 2009; 9: 1043-1055
  57. Stacchiotti S., Collini P., Messina A., Morosi C., Barisella M., Bertulli R., Piovesan C., Dileo P., Torri V., Gronchi A., Casali P.G.: High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 2009; 251: 447-456
  58. Stacchiotti S., Marrari A., Tamborini E., Palassini E., Virdis E., Messina A., Crippa F., Morosi C., Gronchi A., Pilotti S., Casali P.G.: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009; 20: 1886-1894
  59. Stacchiotti S., Tamborini E., Marrari A., Brich S., Arisi Rota S., Orsenigo M., Crippa F., Morosi C., Gronchi A., Pierotti M.A., Casali P.G., Pilotti S.: Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15: 1096-1194
  60. Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Gronchi A, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Cesne AL, Hohenberger P, Blay JY. Eur J Cancer. 2009 Mar 13.
  61. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Eur J Cancer. 2009 Mar 10.
  62. Resection of Uninvolved Adjacent Organs Can Be Part of Surgery for Retroperitoneal Soft Tissue Sarcoma. Gronchi A, Bonvalot S, Le Cesne A, Casali PG. J Clin Oncol. 2009 Mar 9.
  63. High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment--Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG. Radiology. 2009 Mar 4.
  64. Response to sunitinib malate in advanced alveolar soft part sarcoma. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. Clin Cancer Res. 2009 Feb 1;15(3):1096-104.
  65. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Ann Surg Oncol. 2009 Feb;16(2):463-72
  66. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, Casali PG. J Clin Oncol. 2009 Jan 1;27(1):24-30.
  67. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Mol Cancer Ther. 2009 Feb;8(2):449-57.
  68. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A. Eur J Surg Oncol. 2008 Dec 23.
  69. Multimodality treatment of mesenteric desmoid tumours. Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, Demetri GD, George S. Eur J Cancer. 2008 Nov;44(16):2404-10
  70. Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors? Miselli F, Negri T, Gronchi A, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Transl Oncol. 2008 Dec;1(4):177-86.
  71. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG, Gronchi A. Cancer. 2008 Oct 1;113(7):1657-65.
  72. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Ann Oncol. 2008 May;19 Suppl 2:ii89-93.
  73. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Ann Oncol. 2008 May;19 Suppl 2:ii35-8.
  74. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30. Review. Erratum in: J Natl Compr Canc Netw. 2007 Aug;5(7):xxx
  75. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Cancer. 2007 May 1;109(9):1863-9
  76. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Casali PG; Executive Committee of ESMO. Ann Oncol. 2007 Dec;18(12):1923-5.
  77. Combined modalities approach for localized adult extremity soft-tissue sarcoma. Gronchi A, Olmi P, Casali PG. Expert Rev Anticancer Ther. 2007 Aug;7(8):1135-44.
  78. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A. Ann Surg Oncol. 2007 Dec;14(12):3542-51.
  79. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, Casali PG. Ann Oncol. 2008 Jan;19(1):173-7.Free article at journal site
  80. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L. J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4.
  81. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Lancet Oncol. 2007 Jul;8(7):595-602.
  82. Chordoma. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Curr Opin Oncol. 2007 Jul;19(4):367-70.
  83. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG, Gronchi A. Cancer. 2007 Jun 15;109(12):2522-31
  84. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E, Pilotti S. Clin Cancer Res. 2007 Apr 15;13(8):2369-77.
  85. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, Casali PG. Ann Surg. 2007 Mar;245(3):341-6.
  86. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY. Eur J Cancer. 2007 Apr;43(6):974-8. Epub 2007 Mar 2.
  87. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M, Gronchi A. Ann Surg Oncol. 2007 Feb;14(2):553-9.
  88. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Gronchi A, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L, Casali PG. Ann Surg Oncol. 2007 May;14(5):1583-90. Epub 2007 Jan 28.
  89. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S, Bidoli P, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Br J Cancer. 2007 Jan 15;96(1):180-1.
  90. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S. Clin Cancer Res. 2006 Dec 1;12(23):6920-8.
  91. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Lancet. 2006 Oct 14;368(9544):1329-38.
  92. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A. Cancer. 2006 Sep 1;107(5):1065-74.
  93. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P, Issels R, Judson IR, van Oosterom AT, Blay JY. Eur J Cancer. 2006 Sep;42(14):2277-85.
  94. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, Gronchi A, Casali PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Oncogene. 2006 Oct 5;25(45):6140-6.
  95. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, Jimeno J, D'Incalci M, Gescher A, Casali PG. Eur J Cancer. 2006 Jul;42(10):1484-90.
  96. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; The Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. Eur J Cancer. 2006 May;42(8):1093-103.
  97. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S. J Pathol. 2006 Apr;208(5):615-23.
  98. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S. Ann Surg Oncol. 2006 Feb;13(2):229-37.
  99. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C, Gronchi A. Ann Surg Oncol. 2006 Jan;13(1):110-7.
  100. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A. J Clin Oncol. 2005 Oct 20;23(30):7669-75.
  101. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Endocr Relat Cancer. 2005 Sep;12(3):657-66
  102. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD; GIST consensus meeting panelists. Ann Oncol. 2005 Apr;16(4):566-78.
  103. Carney triad: case report and molecular analysis of gastric tumor. Diment J, Tamborini E, Casali P, Gronchi A, Carney JA, Colecchia M. Hum Pathol. 2005 Jan;36(1):112-6.
  104. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Nonaka D, Kusamura S, Baratti D, Casali P, Cabras AD, Younan R, Rosai J, Deraco M. Cancer. 2005 Nov 15;104(10):2181-8.
  105. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR. J Clin Oncol. 2005 Aug 20;23(24):5795-804.
  106. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Eur J Cancer. 2005 Aug;41(12):1751-7.
  107. Adjuvant chemotherapy for soft tissue sarcoma. Casali PG, Picci P. Curr Opin Oncol. 2005 Jul;17(4):361-5.
  108. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. Casali PG, Bertulli R, Fumagalli E, Coco P, Grosso F, Stacchiotti S. J Chemother. 2004 Nov;16 Suppl 4:55-8.
  109. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasiblity study. Kusamura S, Raspagliesi F, Baratti D, Gronchi A, Casali P, Deraco M. J Chemother. 2004 Nov;16 Suppl 5:19-22
  110. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P, Rosai J. J Clin Oncol. 2005 Jan 1;23(1):96-104.
  111. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG, Gronchi A. Cancer. 2005 Jan 15;103(2):402-8.
  112. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34.
  113. Imatinib mesylate in chordoma. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. Cancer. 2004 Nov 1;101(9):2086-97.
  114. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M. Histopathology. 2006 Oct;49(4):381-7
  115. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Cancer. 2004 Aug 1;101(3):627-34.
  116. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S. Gastroenterology. 2004 Jul;127(1):294-9.
  117. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M, Rosai J. Cancer. 2004 Jun 1;100(11):2448-55.
  118. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, Casali PG, Pierotti MA, Pilotti S. Clin Cancer Res. 2004 Feb 1;10(3):938-43.
  119. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG. Cancer. 2003 Aug 1;98(3):571-80.
  120. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. J Clin Oncol. 2003 Apr 1;21(7):1390-7.
  121. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? de Pas T, Casali PG, Toma S, Romanini A, Massidda B, Comandone A, Labianca R, Massacesi C, Tucci A, Antimi M, Biasco G, Aglietta M, Apice G, de Braud F; Italian Sarcoma Group. Oncology. 2003;64(2):186-8.
  122. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R, Kusamura S. J Surg Oncol. 2003 Jul;83(3):147-53.
  123. SYT-SSX fusion genes and prognosis in synovial sarcoma. Mezzelani A, Mariani L, Tamborini E, Agus V, Riva C, Lo Vullo S, Fabbri A, Stumbo M, Azzarelli A, Casali PG, Gronchi A, Sozzi G, Pierotti MA, Pilotti S. Br J Cancer. 2001 Nov 16;85(10):1535-9.
  124. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG. Cancer. 2001 Sep 1;92(5):1259-64.
  125. START: a European state-of-the-art on-line instrument for clinical oncologists. Casali P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F. Ann Oncol. 1999 Jul;10(7):769-73.
Ultimo aggiornamento: mercoledì 11 gennaio 2012

Menu di approfondimento